CMV viremia is associated with poor fungal clearance from cerebrospinal fluid in adult patients with HIV-associated cryptococcal meningitis

Clicks: 10
ID: 332165
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #282 of 297 articles by views in Open forum infectious diseases

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 297 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background Cryptococcosis remains a leading cause of HIV-associated mortality globally. Cytomegalovirus (CMV) viremia is common in advanced HIV disease and is associated with excess mortality through unclear mechanisms. We assessed if CMV viremia is associated with slower rates of Cryptococcus clearance from cerebrospinal fluid (CSF) in persons being treated for HIV-associated cryptococcal meningitis. Methods We quantified baseline CMV DNA using PCR from cryopreserved plasma in adults with cryptococcal meningitis in Uganda from 2010 to 2024. The early fungicidal activity (EFA) was calculated as the negative slope of log10 Cryptococcus colony-forming units (CFU)/mL CSF/day over 18 days. We compared fungal burden, EFA, proportions achieving CSF sterility, and 18-week mortality by CMV status. Results Among 508 participants, 37% had detectable CMV viremia. Median EFA was lower in those with CMV viremia (0.31 vs 0.35 log10 CFU/mL/day; p=0.03), with a greater proportion having EFA <0.20 CFU/mL/day (30.5% vs 22.4%; p=0.04) and with fewer achieving CSF sterility by day 18 (36% vs 54%; p<0.001) than those without CMV viremia. Mortality at 18 weeks was higher in CMV viremic participants (43% vs 26%; p<0.001). Participants with both CMV viremia and EFA <0.20 had 2.5-fold increased hazard of death compared with those without CMV viremia and with EFA >0.20 (adjusted Hazard Ratio = 2.48 [95%CI, 1.52–4.06]). No interaction with antifungal treatment was observed. Conclusions CMV viremia is associated with impaired CSF fungal clearance and increased mortality in HIV-associated cryptococcal meningitis—potentially supporting an immunomodulatory role. Further investigation into the underlying immune response in HIV-CMV co-infection is warranted.
Reference Key
openalex_W7221540674 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors Caleb P Skipper, Timothy Mugabi, Kathy Huppler Hullsiek, Mark Blackstad, Laura Nsangi, Jayne P. Ellis, David B. Meya, Mark R. Schleiss, David R. Boulware
Journal Open forum infectious diseases
Year 2026
DOI
10.1093/ofid/ofag668
URL
https://doi.org/10.1093/ofid/ofag668
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.